TIDMIDH
RNS Number : 1958A
Immunodiagnostic Systems Hldgs PLC
05 October 2009
?
Immunodiagnostic Systems Holdings plc
Trading update
Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading
producer of diagnostic testing kits for the clinical and research markets,
announces a trading update for the six month period to 30 September 2009, prior
to the release of its half-yearly report on Monday, 30 November 2009.
Turnover from continuing operations for the period is 56% ahead of the
comparative period for last year at GBP16.9 million (2008: GBP10.8 million) and
20% ahead of 2008 H2 on a like for like basis. Revenues have increased in all
direct sales territories with substantial growth in the USA, France and
Germany. Sales of our Vitamin D products continue to grow at an impressive rate,
having doubled compared to same period last year.
The company has made progress in both sales and placements of our automated
instrument the IDS-iSYS following its launch at the end of February this year.
We have also launched three automated products; 25 Hydroxy vitamin D at the end
of February, P1NP in July and HGH in September. We have direct reagent rental
accounts in the UK, France, Germany, Austria
and Switzerland and have made instrument sales in Australia, Canada, Finland,
Italy, Spain, France and Switzerland.
The roll out of the IDS-iSYS is in its formative stages, and although initial
machine sales are a little lower than anticipated, it is pleasing to report that
revenue per machine is ahead of expectations. We expect the rate of sales and
placements to increase in H2 following the increase in the number of iSYS
evaluation sites towards the end of H1, the new agreement with Technogenetics
(announced today on RNS Reach) under which we will supply OEM instruments and
reagents to them, and, subject to the timing of FDA approval later this year,
the planned US launch of the iSYS system.
Overall trading remains in line with management expectations and the Board
remains confident going forward that it can continue to execute its plans for
the current year.
Enquiries:
+------------------------------------+------------------------------------+
| Immunodiagnostic Systems Holdings | Tel: 0191 519 0660 |
| Plc | |
+------------------------------------+------------------------------------+
| Roger Duggan, CEO | |
+------------------------------------+------------------------------------+
| Paul Hailes, Finance Director | |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Brewin Dolphin Investment Banking | Tel: 0845 213 4730 |
+------------------------------------+------------------------------------+
| Andrew Emmott | |
| Sean Wyndham-Quin | |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Walbrook PR Ltd | Tel: 020 7933 8787 |
+------------------------------------+------------------------------------+
| Paul McManus | Mob: 07980 541 893 |
+------------------------------------+------------------------------------+
| | paul.mcmanus@walbrookpr.com |
+------------------------------------+------------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTILFLTIRLSIIA
|